Nathan Allen

Nathan Allen

Auto-generated profile, based on publicly available information

Nathan Allen

Auckland University of Technology

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 June 2024 in IEEE Access
Verified
Journal Article
Open access
LKLogan Kenwright
Logan Kenwright
PRPartha Roop
Partha Roop
NANathan Allen
Nathan Allen
SLSanjay Lall
Sanjay Lall
CCCălin Caşcaval
Călin Caşcaval
MIMartin Izzard
Martin Izzard
In the modelling of distributed systems, most Models of Computation (MoCs) rely on blocking communication to preserve determinism. A prominent example is Kahn Process Networks (KPNs), which supports non-blocking writes and blocking reads, and its implementable variant Finite FIFO Platforms (FFPs) which enforces boundedness using blocking writes. An issue with these models is that they mix process synchronisation with process execution, necessitating frequent blocking during synchronisation. This paper explores a recent alternative called bittide , which decouples the execution of a process from the synchronisation behaviour. Determinism and boundedness is preserved while enabling pipelined execution for better throughput. To understand the behaviour of these systems we define a formal model – a deterministic MoC called Logical Synchrony Networks (LSNs). LSNs describes a network of processes modelled as a graph, with edges representing invariant logical delays between a producer process and the corresponding consumer process. We show that this abstraction is satisfied by the KPN model, and subsequently by both the concrete FFPs and bittide architectures. Thus, we show that FFPs and bittide offer two ways of implementing deterministic distributed systems, with the latter being more performant.

15 April 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
NANathan Allen
Nathan Allen
AJAron Jeremiah
Aron Jeremiah
RMRobin Murphy
Robin Murphy
RSRachael Sumner
Rachael Sumner
AFAnna Forsyth
Anna Forsyth
PRPartha Roop
Partha Roop
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses self-administered every third day. Participants used a commercially available sleep/activity tracker for the duration of the trial. Data from 3231 nights of sleep showed that on the night after microdosing, participants in the LSD group slept an extra 24.3 min per night (95% Confidence Interval 10.3–38.3 min) compared to placebo—with no reductions of sleep observed on the dosing day itself. There were no changes in the proportion of time spent in various sleep stages or in participant physical activity. These results show a clear modification of the physiological sleep requirements in healthy male volunteers who microdose LSD. The clear, clinically significant changes in objective measurements of sleep observed are difficult to explain as a placebo effect. Trial registration: Australian New Zealand Clinical Trials Registry: A randomized, double-blind, placebo-controlled trial of repeated microdoses of lysergic acid diethylamide (LSD) in healthy volunteers; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476; ACTRN12621000436875.

5 November 2025 in Neuropharmacology
Verified
Journal Article
Open access
DDDimitri Daldegan-Bueno
Dimitri Daldegan-Bueno
CDCarina Joy Donegan
Carina Joy Donegan
RSRachael Sumner
Rachael Sumner
AFAnna Forsyth
Anna Forsyth
WEWilliam Evans
William Evans
SMSuresh Muthukumaraswamy
Suresh Muthukumaraswamy
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various mental health disorders. This study evaluated the feasibility and tolerability of an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label phase 2A trial (LSDDEP1). Nineteen participants (15 male), most of whom were taking an antidepressant medication (n = 15), took 16 doses of LSD (8 μg initially, then 6-20 μg twice weekly at home), with the first dose administered in the clinic. We assessed tolerability through withdrawal rates due to adverse events and feasibility by clinic visit attendance. Safety measures included adverse events, blood laboratory tests, electrocardiography (ECG), and echocardiography. Depression was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS). No serious or severe adverse events and clinical alterations in safety measures were observed, being this the first study to evaluate valvulopathy after repeated psychedelic administration in humans. One participant withdrew due to experiencing anxiety when dosing; all scheduled clinic visits were attended. MADRS scores were reduced by 59.5 % at the end of the intervention and were sustained for up to six months. Improvements were also noted in anxiety, rumination, stress, and quality of life. While limited by an open-label design and small sample size, this study provides preliminary evidence supporting the safety and feasibility of treating moderate depression with microdosed LSD and underscores a need for further randomised controlled trials. Trial registration: ANZCTR, ACTRN12623000486628 (12 May 2023).

18 February 2026 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
DDDimitri Daldegan-Bueno
Dimitri Daldegan-Bueno
CDCarina Joy Donegan
Carina Joy Donegan
RSRachael Sumner
Rachael Sumner
AFAnna Forsyth
Anna Forsyth
SJSoo Hee Jeong
Soo Hee Jeong
SMSuresh Muthukumaraswamy
Suresh Muthukumaraswamy
Despite growing interest in microdosed psychedelics, clinical trial evidence remains limited. We present daily mood, subjective perception of effects, and pharmacokinetics from an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label trial in which participants reported a mean symptom reduction of 60%. Participants took 16 sublingual LSD doses: 8 μg onsite, with bloods collected at eight time-points, then twice weekly at home with titration (6-20 μg). Pharmacokinetic parameters were estimated using non-compartmental and compartmental modelling. Daily questionnaires were used to assess depression severity with the self-reported Hamilton Depression Rating Scale (HAMD6), and mood with visual analogue scales (VAS). Drug effects were recorded with VAS scales on each dosing day. Linear mixed models were used to compare dosing days to one- and two-day post-dosing, and to identify linear trends (tolerance/sensitisation) of drug effects. Nineteen participants (males n = 15, 79%) received the intervention. Daily VAS indicated increased scores of mood-related states (e.g., more creative, happier) on dosing days (p = 0.009 to 0.039), but not in depression (p = 0.291). There was no indication of tolerance or sensitisation (p > 0.081). Non-compartmental AUC0-tlast was 836 ± 319 pg.h/mL, Cmax 212 ± 77.7 pg/mL and Tmax 1.17 ± 0.56 h. Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.

12 October 2024
Verified
Book Chapter
Closed access
PDF file
SVSai Rohan Harshavardhan Vuppala
Sai Rohan Harshavardhan Vuppala
NANathan Allen
Nathan Allen
SPSrinivas Pinisetty
Srinivas Pinisetty
PRPartha Roop
Partha Roop